Pharmaceutical companies “are doing everything in their power” to minimise disruption to the supply of medicines should the UK leave the EU under a ‘no-deal’ scenario, but a deal is urgently needed to fully protect patients, MPs have been told.
News
Healthcare communications at its best
The Communications Team of the Year Awards will take place at The Tower Hotel, London on Thursday 15 November, alongside Marketer of the Year and the all-new Sales Awards.
Celebrating sales and marketing excellence
Such is the link between the two disciplines, Marketer of the Year will celebrate its 25th anniversary at The Tower Hotel, London on Thursday 15 November, alongside the all-new Sales Awards.
XLH patients to get routine access to first new therapy in 30 years
For the first time in more than 30 years children and young adults in England and Wales with the rare bone disorder XLH will have access to a new treatment option via the NHS.
Novartis crizanlizumab shows promise in sickle cell anaemia
A new analysis has shown that Novartis’ crizanlizumab reduced the number of patients with sickle cell disease experiencing a pain crisis.
Affimed shares plunge on trial death
Shares in German biopharma Affimed dropped near 30% after the company said it was placing a key Phase I programme of its experimental cancer immunotherapy on hold because of serious side effects observed in trials, including a patient death.
Diurnal shares plummet on trial failure
Shares in UK speciality pharma Diurnal plummeted more than 50 percent on news that a late-stage study of an experimental treatment for congenital adrenal hyperplasia (CAH) failed to meet its primary objective.
The PharmaTimes Medical & Scientific Excellence Awards – could it be you?
Do you have a passion for medical information? Could you be among the first in the field to win at the hotly anticipated PharmaTimes Medical & Scientific Excellence Awards?
Novartis files MS drug siponimod in EU and US
Novartis is seeking approval on both sides of the Atlantic for use of experimental multiple sclerosis therapy siponimod to treat secondary progressive forms of the disease.
New UK biopharma Sitryx launches with $30m fundraising
New UK biopharmaceutical group Sitryx has launched operations with $30 million to help it develop disease-modifying therapeutics in immunometabolism.
Mixed data for Xencor’s SLE drug
Xencor’s experimental systemic lupus erythematosus (SLE) drug XmAb5871 has failed to hit its key target in a mid-stage study.
Four new therapies to be funded by NHS Scotland
The Scottish Medicines Consortium has endorsed NHS funding for four therapies, offering new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis.
Stelara induces remission in ulcerative colitis patients
Janssen has presented new data showing that a single dose of its biologic Stelara induced clinical remission and response in patients with moderate to severe ulcerative colitis.
NICE expands backing for Pfizer’s Mylotarg
NICE is recommending Mylotarg for previously untreated, de novo, CD33-positive acute myeloid leukaemia in combination with chemotherapy.
US nod for Akcea/Ionis’ Tegsedi
Akcea and Ionis’ Tegsedi has won US approval for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
